Literature DB >> 11561936

A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments.

C G Ballard1, M Margallo-Lana, J Fossey, K Reichelt, P Myint, D Potkins, J O'Brien.   

Abstract

BACKGROUND: Behavioral and psychological symptoms in dementia (BPSD) are common and distressing for patients and caregivers, but little is known about the natural history of these symptoms, particularly among patients in care facilities. This information is essential for informed clinical management. We report a 1-year follow-up study of the prevalence, incidence, and outcome of the 3 main BPSD (agitation, depression, and psychosis) in care facilities.
METHOD: 136 elderly residents with dementia (29% living in social care facilities and 71% in nursing home care) were assessed longitudinally on 2 occasions a year apart using a range of standardized psychiatric schedules, including the Neuropsychiatric Inventory.
RESULTS: The overall prevalence of BPSD was stable over the year (76% at baseline and 82% at follow-up). Subjects with subclinical symptoms at baseline were more likely to develop clinically significant BPSD during follow-up than those who were symptom free (83% vs. 52%; Mann-Whitney U test, z = 2.36, p = .01). Agitation was the most common individual syndrome (55%). Although overall BPSD were persistent, > or = 45% of dementia patients with any of the major syndromes experienced resolution, indicating the development of different BPSD in many residents. There was no evidence that residents taking neuroleptics were more likely to experience resolution of BPSD than neuroleptic-free residents.
CONCLUSION: BPSD are highly frequent and persistent among residents of care facilities with dementia. This emphasizes the need for ongoing treatment trials. The pattern of resolution with the development of new symptoms indicates that short focused periods of treatment may be a more effective management approach. In addition, the potential value in treating patients with subclinical BPSD to prevent the development of full-blown syndromes needs to be investigated.

Entities:  

Mesh:

Year:  2001        PMID: 11561936     DOI: 10.4088/jcp.v62n0810

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  25 in total

1.  Neuropsychiatric symptoms in Alzheimer's disease.

Authors:  Constantine G Lyketsos; Maria C Carrillo; J Michael Ryan; Ara S Khachaturian; Paula Trzepacz; Joan Amatniek; Jesse Cedarbaum; Robert Brashear; David S Miller
Journal:  Alzheimers Dement       Date:  2011-09       Impact factor: 21.566

2.  Cognitive and neuropsychiatric impairments in Alzheimer's disease: current treatment strategies.

Authors:  Anna Borisovskaya; Marcella Pascualy; Soo Borson
Journal:  Curr Psychiatry Rep       Date:  2014-09       Impact factor: 5.285

3.  Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovascular events. A controlled, open-label study.

Authors:  Rita Moretti; Paola Torre; Rodolfo M Antonello; Tatiana Cattaruzza; Giuseppe Cazzato
Journal:  J Neurol       Date:  2005-04-13       Impact factor: 4.849

Review 4.  Risperidone for the treatment of neuropsychiatric features in dementia.

Authors:  Alistair Burns; Peter P De Deyn
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 5.  Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review.

Authors:  Philip E Lee; Sudeep S Gill; Morris Freedman; Susan E Bronskill; Michael P Hillmer; Paula A Rochon
Journal:  BMJ       Date:  2004-06-11

6.  Dementia Care Mapping™ to reduce agitation in care home residents with dementia: the EPIC cluster RCT.

Authors:  Claire A Surr; Ivana Holloway; Rebecca Ea Walwyn; Alys W Griffiths; David Meads; Rachael Kelley; Adam Martin; Vicki McLellan; Clive Ballard; Jane Fossey; Natasha Burnley; Lynn Chenoweth; Byron Creese; Murna Downs; Lucy Garrod; Elizabeth H Graham; Amanda Lilley-Kelley; Joanne McDermid; Holly Millard; Devon Perfect; Louise Robinson; Olivia Robinson; Emily Shoesmith; Najma Siddiqi; Graham Stokes; Daphne Wallace; Amanda J Farrin
Journal:  Health Technol Assess       Date:  2020-03       Impact factor: 4.014

7.  Improving person-centred care in nursing homes through dementia-care mapping: design of a cluster-randomised controlled trial.

Authors:  Geertje van de Ven; Irena Draskovic; Eddy M M Adang; Rogier A R T Donders; Aukje Post; Sytse U Zuidema; Raymond T C M Koopmans; Myrra J F J Vernooij-Dassen
Journal:  BMC Geriatr       Date:  2012-01-03       Impact factor: 3.921

8.  A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial).

Authors:  Clive Ballard; Marisa Margallo Lana; Megan Theodoulou; Simon Douglas; Rupert McShane; Robin Jacoby; Katja Kossakowski; Ly-Mee Yu; Edmund Juszczak
Journal:  PLoS Med       Date:  2008-04-01       Impact factor: 11.069

9.  The efficacy of mirtazapine in agitated patients with Alzheimer's disease: A 12-week open-label pilot study.

Authors:  Sibel Cakir; Isin Baral Kulaksizoglu
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

10.  Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis.

Authors:  Noll Campbell; Amir Ayub; Malaz A Boustani; Chris Fox; Martin Farlow; Ian Maidment; Robert Howards
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.